Vandetanib for the treatment of thyroid cancer: an update
Spyridon Karras1, Panagiotis Anagnostis, Gerasimos E Krassas
1Panagia General Hospital, Department of Endocrinology, Diabetes and Metabolism , Venizelou 34b 55535, Thessaloniki , Greece +30 2310324863 ; +30 2310324863 ; karraspiros@yahoo.gr.
Introduction:
Medullary thyroid carcinoma (MTC) is a rare endocrine malignancy accounting for a significant percentage of thyroid cancer-related fatal events. Traditional treatment modalities used in the other types of thyroid carcinomas have been proved largely ineffective in advanced MTC. Better understanding of the molecular pathways implicated in the pathogenesis of MTC has led to the development of new drugs, which are implicated in the disruption of these molecular cascades.
Areas Covered:
This review provides the latest information regarding vandetanib , a new tyrosine kinase inhibitor mainly in the treatment of MTC. A collection of available data was conducted using the PubMed database as well as the ClinicalTrials.gov website, searching for vandetanib and thyroid cancer.
Expert Opinion:
Vandetanib targets multiple cell-signaling pathways involved in the molecular pathogenesis of thyroid cancer, namely vascular endothelial growth factor receptor-2, epidermal growth factor receptor and rearranged during transfection receptor. It is an effective approach in treating advanced MTC. However, treatment toxicity issues, as well as individual patient parameters, including disease burden and progression, should be taken into consideration before initiating vandetanib treatment.
Insights
Vandetanib is an effective treatment for advanced medullary thyroid carcinoma (MTC) by targeting key molecular pathways. Patient-specific factors and toxicity must be considered before initiating this tyrosine kinase inhibitor therapy.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Medullary thyroid carcinoma (MTC) is a rare, aggressive endocrine malignancy.
- Conventional treatments are often ineffective for advanced MTC.
- Molecular pathway understanding has led to targeted therapies.
Purpose of the Study:
- To review the latest information on vandetanib for MTC treatment.
- To summarize vandetanib's mechanism of action and efficacy.
- To discuss considerations for vandetanib therapy in MTC.
Main Methods:
- Literature review of vandetanib in MTC.
- Data collection from PubMed and ClinicalTrials.gov.
- Focus on tyrosine kinase inhibitors in thyroid cancer.
Main Results:
- Vandetanib targets VEGFR-2, EGFR, and RET pathways.
- It demonstrates efficacy in treating advanced MTC.
- Toxicity and individual patient parameters are crucial.
Conclusions:
- Vandetanib is a valuable targeted therapy for advanced MTC.
- Treatment decisions require careful consideration of patient-specific factors.
- Further research into optimizing vandetanib therapy is warranted.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies